1. 視力正常或完全色弱的人不會看到數字。那些有紅綠色弱的人看到「5」 
2. 視力正常者會看到「紫色」及「紅色」線條。那些有紅色弱的人看到「紫色」線條。那些有弱紅色視覺患者看到「紅色」線條。那些有綠色弱的人看到「紅色」線條。那些有弱綠色視覺患者看到「紫色」線條。
3. 視力正常者看到「綠色」線條。大多數具有任何色弱的患者，無法看到線條。
. 色覺正常者看到「黃藍綠色」線條。那些有紅綠色弱的人看到「藍綠色」或「紅色」線條。完全色弱的患者無法看到任何顏色的線條。
5. 任何人士都可以看到線條。
6. 視力正常或完全色弱的人不會看到數字。那些有紅綠色弱的人看到「45」。
Previous studies have documented the increased cardiovascular risk associated with the use of some nonsteroidal anti-inflammatory drugs (NSAIDs). Despite this, many old NSAIDs are still prescribed worldwide. Most of the studies to date have been focused on specific oral drugs or limited by the number of cases examined. We studied the risk of new acute myocardial infarction (AMI) hospitalization with current use of a variety of oral and parenteral NSAIDs in a nationwide population, and compared our results with existing evidence.
We conducted a case-crossover study using the Taiwan's National Health Insurance claim database, identifying patients with new AMI hospitalized in 2006. The 1-30 days and 91-120 days prior to the admission were defined as case and matched control period for each patient, respectively. Uses of NSAIDs during the respective periods were compared using conditional logistic regression and adjusted for use of co-medications.
8354 new AMI hospitalization patients fulfilled the study criteria. 14 oral and 3 parenteral NSAIDs were selected based on drug utilization profile among 13.7 million NSAID users. The adjusted odds ratio, aOR (95% confidence interval), for risk of AMI and use of oral and parenteral non-selective NSAIDs were 1.42 (1.29, 1.56) and 3.35 (2.50, 4.47), respectively, and significantly greater for parenteral than oral drugs (p for interaction < 0.01). Ketorolac was associated with the highest AMI risk among both of oral and parenteral NSAIDs studied, the aORs were 2.02 (1.00, 4.09) and 4.27 (2.90, 6.29) respectively. Use of oral flurbiprofen, ibuprofen, sulindac, diclofenac, and parenteral ketoprofen were also significantly associated with increased AMI risk. The results of the present study were consistent with the majority of evidence from previous studies.
The collective evidence revealed the tendency of increased AMI risk with current use of some NSAIDs. A higher AMI risk associated with use of parenteral NSAIDs was observed in the present study. Ketorolac had the highest associated risk in both oral and parenteral NSAIDs studied. Though further investigation to confirm the association is warranted, prescribing physicians and the general public should be cautious about the potential risk of AMI when using NSAIDs.
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for reducing inflammation and relief pain. Due to large population exposed to NSAIDs, the risk of serious adverse cardiovascular effect for patient taking NSAIDs is an area of concern, from both a clinical and public health perspective [1-9]. Despite the frequent prescription of a wide variety of old oral and parenteral NSAIDs, recent studies exploring links between cardiovascular risk and NSAIDs use, including randomized controlled trials and observational studies, had mostly focused on cyclooxygenase-2 selective inhibitors (COX-2) or some non-selective NSAIDs (ns-NSAIDs), and were limited by the number of cases examined [1-3,10-12]. The assessment of the risk of acute myocardial infarction (AMI) from the use of parenteral NSAIDs was not a focus of the studies. The aim of this study was to assess the risk of hospitalization due to AMI as a result of the use of a variety of oral and parenteral NSAIDs in outpatient-clinic settings, and to compare the results with existing evidence.
2026-08-19 高雄醫師公會 家醫2.0線上課程 腎絲球高壓的病患. 有一半會被 eGFR 低估 1.血糖 > 180 尿糖開始出現 2.再吸收- SGLT2 不夠用 3.鈉離子減少 4.TGF啟動 5.入球小動脈擴張 6. 腎絲球高壓 7. 足細胞...... 等等...
